Pfizer’s RSV vaccine just won an FDA panel’s backing for safety in older people. It’s a market that will be worth up to $10 billion in a decade
Pfizer Inc.’s vaccine for respiratory syncytial virus obtained backing from a panel of US advisers ...
Read more
